Coronavirus Update: Pfizer/BioNTech Vaccine Shows Antibody Response In Young Kids
Plus, Vaccine Progress In India
Executive Summary
The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light, and vaccines from other Indian firms progress.